TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's lead therapeutic candidate TTX-MC138 ...
NEW YORK – TransCode Therapeutics' microRNA-10b inhibitor TTX-MC138 will be included in a Phase II branch of the PRE-I-SPY trial, the company announced Thursday.
TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate
BOSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced ...
Live transcoding on the web has quickly evolved into the optimal workflow for streaming live events. In this schema, you send a single efficient stream to the cloud, transcode the stream to produce a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback